Renchi Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Renchi Yang has a total of 499 co-authors. Here are the top co-authors by number of shared publications:
Huiyuan Li
State Key Laboratory of Experimental Hematology; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Tianjin Laboratory of Blood Disease Gene Therapy; CAMS Key Laboratory of Gene Therapy for Blood Diseases
35 shared publicationsFeng Xue
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
32 shared publicationsXiaofan Liu
State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
30 shared publicationsLei Zhang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
26 shared publications- Feng Xue
State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
25 shared publications - Lei Zhang
State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
24 shared publications
Latest Publications
- 16 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3853-3861
Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial
- 16 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3853-3861
Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial
- Open Access
- 28 August 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (6)
Denecimig (Mim8) prophylaxis over 52 weeks in adolescents and adults with hemophilia A: FRONTIER2 extension study
- 28 August 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (6)
Open AccessDenecimig (Mim8) prophylaxis over 52 weeks in adolescents and adults with hemophilia A: FRONTIER2 extension study
- 15 June 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (3) , 1269-1279
Long‐term outcomes with emicizumab prophylaxis for haemophilia A in China: A multicentre, large‐cohort retrospective study
Summary: Emicizumab is an established prophylactic therapy for haemophilia A (HA). However, real‐world multicentre evidence on long‐term outcomes, particularly in a resource‐constrained setting, remains limited. We aimed to evaluate real‐world outcomes in patients with HA receiving emicizumab prophylaxis across multiple centres with extended follow‐up. We conducted a multicentre retrospective study of patients with HA who received emicizumab prophylaxis for ≥1 year across 25 centres. Outcomes included annualized bleeding rate (ABR), annualized joint bleeding rate (AJBR), bleeding events, target joint status and adverse events. A total of 132 patients (131 males and 1 female) were included, with a median age at switch of 2.0 years (interquartile range [IQR], 1.0–4.8). Over a median follow‐up of 26 months (IQR: 16.0–40.0), the negative binomial regression model‐based ABR for all bleeds was 0.81 (95% confidence interval [CI], 0.62–1.07). Across 12‐month intervals, both calculated mean and negative binomial regression model‐based AJBR remained between 0.1 and 0.3. Of the 74 baseline target joints, 95.9% ( n = 71) resolved and no new target joints developed. Forty‐two patients (31.8%) received factor concentrates during emicizumab treatment. Injection‐site reactions occurred in 7.6% of patients, with no thromboembolic or fatal events observed. Long‐term emicizumab prophylaxis provides sustained bleeding control, joint protection and a favourable safety profile.
- 15 June 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (3) , 1269-1279
Long‐term outcomes with emicizumab prophylaxis for haemophilia A in China: A multicentre, large‐cohort retrospective study
Summary: Emicizumab is an established prophylactic therapy for haemophilia A (HA). However, real‐world multicentre evidence on long‐term outcomes, particularly in a resource‐constrained setting, remains limited. We aimed to evaluate real‐world outcomes in patients with HA receiving emicizumab prophylaxis across multiple centres with extended follow‐up. We conducted a multicentre retrospective study of patients with HA who received emicizumab prophylaxis for ≥1 year across 25 centres. Outcomes included annualized bleeding rate (ABR), annualized joint bleeding rate (AJBR), bleeding events, target joint status and adverse events. A total of 132 patients (131 males and 1 female) were included, with a median age at switch of 2.0 years (interquartile range [IQR], 1.0–4.8). Over a median follow‐up of 26 months (IQR: 16.0–40.0), the negative binomial regression model‐based ABR for all bleeds was 0.81 (95% confidence interval [CI], 0.62–1.07). Across 12‐month intervals, both calculated mean and negative binomial regression model‐based AJBR remained between 0.1 and 0.3. Of the 74 baseline target joints, 95.9% ( n = 71) resolved and no new target joints developed. Forty‐two patients (31.8%) received factor concentrates during emicizumab treatment. Injection‐site reactions occurred in 7.6% of patients, with no thromboembolic or fatal events observed. Long‐term emicizumab prophylaxis provides sustained bleeding control, joint protection and a favourable safety profile.
- Open Access
- 1 June 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 111 (6) , 2180-2181
Erratum to: “Multilevel defects in the hematopoietic niche in essential thrombocythemia”
- 1 June 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 111 (6) , 2180-2181
Open AccessErratum to: “Multilevel defects in the hematopoietic niche in essential thrombocythemia”
- Open Access
- 1 June 2026
- Published by KEAI Publishing in Global Medical Genetics
- Vol. 13 (2) , 100107
No significant increase in thrombotic risk following the widespread adoption of TPO-RAs in ITP: A comparative study
In patients with primary immune thrombocytopenia (ITP), the risk of thrombosis associated with thrombopoietin receptor agonists (TPO-RAs) remains debated. This study compared the thrombosis occurrence in ITP patients before and after the launch of TPO-RAs in China, to explore the relationship between TPO-RAs and thrombosis in ITP patients. Data from 2005 to 2017 were obtained from an article published by the Blood Disease Hospital, Chinese Academy of Medical Sciences in 2018. The present study included 1915 hospitalized patients in the same center from January 2018 to February 2025. Among these, thrombosis events occurred in 33 cases (1.72%). The incidence of arterial thrombosis was higher than that of venous thrombosis. Male gender, age over 40 years old, hypertension, diabetes, smoking, and TPO-RAs were associated with thrombosis. Neither platelet count nor stage of ITP showed a significant effect on thrombosis risk. Although the utilization rate of TPO-RAs increased significantly after 2018, no corresponding significant change in thrombosis incidence was observed. These findings suggest that thrombosis in ITP patients results from the interplay of multiple risk factors. While the widespread use of TPO-RAs does not appear to increase the overall risk of thrombosis in ITP patients, caution is still advised when administering these agents to patients with pre-existing thrombosis risk factors.
- 1 June 2026
- Published by KEAI Publishing in Global Medical Genetics
- Vol. 13 (2) , 100107
Open AccessNo significant increase in thrombotic risk following the widespread adoption of TPO-RAs in ITP: A comparative study
In patients with primary immune thrombocytopenia (ITP), the risk of thrombosis associated with thrombopoietin receptor agonists (TPO-RAs) remains debated. This study compared the thrombosis occurrence in ITP patients before and after the launch of TPO-RAs in China, to explore the relationship between TPO-RAs and thrombosis in ITP patients. Data from 2005 to 2017 were obtained from an article published by the Blood Disease Hospital, Chinese Academy of Medical Sciences in 2018. The present study included 1915 hospitalized patients in the same center from January 2018 to February 2025. Among these, thrombosis events occurred in 33 cases (1.72%). The incidence of arterial thrombosis was higher than that of venous thrombosis. Male gender, age over 40 years old, hypertension, diabetes, smoking, and TPO-RAs were associated with thrombosis. Neither platelet count nor stage of ITP showed a significant effect on thrombosis risk. Although the utilization rate of TPO-RAs increased significantly after 2018, no corresponding significant change in thrombosis incidence was observed. These findings suggest that thrombosis in ITP patients results from the interplay of multiple risk factors. While the widespread use of TPO-RAs does not appear to increase the overall risk of thrombosis in ITP patients, caution is still advised when administering these agents to patients with pre-existing thrombosis risk factors.
- Open Access
- 23 April 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (17) , 1984-1998
Single-cell profiling of ANKRD26 thrombocytopenia reveals progenitor expansion and polyploid apoptosis via JUNB-p21
ANKRD26-related thrombocytopenia 2 (THC2) is a rare inherited platelet disorder caused by germ line variants in the 5′ untranslated region (UTR) of ANKRD26. Although prior studies using in vitro models or isolated case reports have suggested impaired megakaryopoiesis as a central mechanism, detailed insights have remained elusive, primarily due to the rarity, fragility, and heterogeneity of megakaryocytes (MKs). Here, we present a comprehensive, crossvalidated analysis of bone marrow samples from 4 independent patients with THC2, integrating single-cell transcriptomics and ex vivo functional profiling. Across all patients, we analyzed CD34+ hematopoietic stem and progenitor cells (HSPCs; 47 281 THC2 HSPCs vs 51 907 control cells) and primary MKs (pMKs; 7309 THC2 pMKs vs 5077 control cells), uncovering a consistent pattern of MK progenitors (MkP) expansion and a marked reduction in polyploid MKs, indicating a conserved pathophysiologic phenotype. In our index patient, we identified the 5′ UTR single-nucleotide variant in ANKRD26 that led to significantly elevated expression across 4 MK lineage subsets, spanning multipotent progenitors, common myeloid progenitors, MK-erythroid progenitors, and MkP as well as in terminally enriched pMKs. Confocal imaging localized ANKRD26 to the centrosome, implicating it in mitotic regulation during MK maturation. Mechanistically, we discovered that elevated ANKRD26 induces apoptosis in polyploid MKs via JUNB-mediated transcriptional activation of CDKN1A (p21), operating independently of the canonical p53-PIDDosome axis. This multipatient study provided the most comprehensive cellular and molecular portrait of ANKRD26-driven thrombocytopenia to date, offering novel insights into defective megakaryopoiesis and identifying candidate therapeutic targets to restore platelet production.
- 23 April 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (17) , 1984-1998
Open AccessSingle-cell profiling of ANKRD26 thrombocytopenia reveals progenitor expansion and polyploid apoptosis via JUNB-p21
ANKRD26-related thrombocytopenia 2 (THC2) is a rare inherited platelet disorder caused by germ line variants in the 5′ untranslated region (UTR) of ANKRD26. Although prior studies using in vitro models or isolated case reports have suggested impaired megakaryopoiesis as a central mechanism, detailed insights have remained elusive, primarily due to the rarity, fragility, and heterogeneity of megakaryocytes (MKs). Here, we present a comprehensive, crossvalidated analysis of bone marrow samples from 4 independent patients with THC2, integrating single-cell transcriptomics and ex vivo functional profiling. Across all patients, we analyzed CD34+ hematopoietic stem and progenitor cells (HSPCs; 47 281 THC2 HSPCs vs 51 907 control cells) and primary MKs (pMKs; 7309 THC2 pMKs vs 5077 control cells), uncovering a consistent pattern of MK progenitors (MkP) expansion and a marked reduction in polyploid MKs, indicating a conserved pathophysiologic phenotype. In our index patient, we identified the 5′ UTR single-nucleotide variant in ANKRD26 that led to significantly elevated expression across 4 MK lineage subsets, spanning multipotent progenitors, common myeloid progenitors, MK-erythroid progenitors, and MkP as well as in terminally enriched pMKs. Confocal imaging localized ANKRD26 to the centrosome, implicating it in mitotic regulation during MK maturation. Mechanistically, we discovered that elevated ANKRD26 induces apoptosis in polyploid MKs via JUNB-mediated transcriptional activation of CDKN1A (p21), operating independently of the canonical p53-PIDDosome axis. This multipatient study provided the most comprehensive cellular and molecular portrait of ANKRD26-driven thrombocytopenia to date, offering novel insights into defective megakaryopoiesis and identifying candidate therapeutic targets to restore platelet production.
- Open Access
- 2 April 2026
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 139 (16) , 2505-2507
Emicizumab prophylaxis in children with hemophilia A with factor VIII inhibitors in China (HAVEN 5)
- 2 April 2026
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 139 (16) , 2505-2507
Open AccessEmicizumab prophylaxis in children with hemophilia A with factor VIII inhibitors in China (HAVEN 5)
- Open Access
- 27 March 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (3)
The therapeutic landscape of inherited bleeding disorders in China
- 27 March 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (3)
Open AccessThe therapeutic landscape of inherited bleeding disorders in China
- Open Access
- 13 February 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Recombinant von Willebrand factor for von Willebrand disease: mechanism of action and clinical application
Von Willebrand disease (VWD) is an inherited bleeding disorder resulting from a deficiency in von Willebrand factor (VWF), either quantitative or qualitative. Recombinant VWF (rVWF) presents a novel therapeutic option for patients with VWD. Produced in Chinese hamster ovary cells, rVWF is free of animal or human plasma proteins, thus eliminating the risk of pathogen transmission. It preserves the full range of VWF multimers, including ultra-large multimers, which are essential for hemostasis. Research indicates that rVWF demonstrates superior pharmacokinetics and pharmacodynamics compared to plasma-derived VWF, offering a longer terminal half-life, enhanced platelet adhesion and aggregation, and more robust factor VIII stabilization. These properties contribute to rVWF’s increased hemostatic efficacy in managing bleeding episodes and perioperative surgical bleeding in adults and children with VWD, as well as the routine prophylaxis for adults to reduce the frequency of bleeding episodes. Furthermore, rVWF is well-tolerated with a low thrombotic risk, making it a promising treatment option and addressing a significant clinical need globally.
- 13 February 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Open AccessRecombinant von Willebrand factor for von Willebrand disease: mechanism of action and clinical application
Von Willebrand disease (VWD) is an inherited bleeding disorder resulting from a deficiency in von Willebrand factor (VWF), either quantitative or qualitative. Recombinant VWF (rVWF) presents a novel therapeutic option for patients with VWD. Produced in Chinese hamster ovary cells, rVWF is free of animal or human plasma proteins, thus eliminating the risk of pathogen transmission. It preserves the full range of VWF multimers, including ultra-large multimers, which are essential for hemostasis. Research indicates that rVWF demonstrates superior pharmacokinetics and pharmacodynamics compared to plasma-derived VWF, offering a longer terminal half-life, enhanced platelet adhesion and aggregation, and more robust factor VIII stabilization. These properties contribute to rVWF’s increased hemostatic efficacy in managing bleeding episodes and perioperative surgical bleeding in adults and children with VWD, as well as the routine prophylaxis for adults to reduce the frequency of bleeding episodes. Furthermore, rVWF is well-tolerated with a low thrombotic risk, making it a promising treatment option and addressing a significant clinical need globally.
- Open Access
Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial
Objective: To assess the efficacy and safety of CM313, an anti-CD38 monoclonal antibody, in adults with persistent or chronic primary immune thrombocytopenia. Design: Multicentre, randomised, placebo controlled, phase 2 trial. Setting: Five hospitals in China, 16 January to 11 June 2024. Participants: 45 patients aged ≥18 years with persistent or chronic immune thrombocytopenia who failed to respond to, or relapsed after, glucocorticoid treatment but had previously responded to standard first line treatment. Interventions: Patients were randomised to receive intravenous CM313 (16 mg/kg) or placebo weekly for eight weeks. Main outcome measures: The primary outcome was overall response rate (at least two consecutive platelet counts ≥30×10 9 /L, a minimum doubling from baseline, and no bleeding) at week 8. A secondary outcome was time to the first two consecutive platelet counts ≥50×10 9 /L. Results: Of 56 patients screened, 45 were randomised to receive CM313 (n=30) or placebo (n=15). At week 8, the overall response rate was higher in the CM313 group (83%; 25/30) compared with placebo group (20%; 3/15): difference 63.3% (95% confidence interval 33.7% to 81.3%; P9 /L was one week in the CM313 group but was not reached in the placebo group (P9 /L was 18 weeks in the CM313 group versus three weeks in the placebo group (P=0.004). Treatment emergent adverse events occurred in 87% (26/30) of patients in the CM313 group and 80% (12/15) in the placebo group, with infusion related reactions and petechiae being the most common. Conclusion: CM313 showed a favourable safety profile and encouraging efficacy in adults with persistent or chronic primary immune thrombocytopenia, characterised by rapid increase in platelet count, sustained platelet responses, and manageable adverse events. Trial registration: ClinicalTrials.gov NCT06199089 .
Open AccessAnti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial
Objective: To assess the efficacy and safety of CM313, an anti-CD38 monoclonal antibody, in adults with persistent or chronic primary immune thrombocytopenia. Design: Multicentre, randomised, placebo controlled, phase 2 trial. Setting: Five hospitals in China, 16 January to 11 June 2024. Participants: 45 patients aged ≥18 years with persistent or chronic immune thrombocytopenia who failed to respond to, or relapsed after, glucocorticoid treatment but had previously responded to standard first line treatment. Interventions: Patients were randomised to receive intravenous CM313 (16 mg/kg) or placebo weekly for eight weeks. Main outcome measures: The primary outcome was overall response rate (at least two consecutive platelet counts ≥30×10 9 /L, a minimum doubling from baseline, and no bleeding) at week 8. A secondary outcome was time to the first two consecutive platelet counts ≥50×10 9 /L. Results: Of 56 patients screened, 45 were randomised to receive CM313 (n=30) or placebo (n=15). At week 8, the overall response rate was higher in the CM313 group (83%; 25/30) compared with placebo group (20%; 3/15): difference 63.3% (95% confidence interval 33.7% to 81.3%; P9 /L was one week in the CM313 group but was not reached in the placebo group (P9 /L was 18 weeks in the CM313 group versus three weeks in the placebo group (P=0.004). Treatment emergent adverse events occurred in 87% (26/30) of patients in the CM313 group and 80% (12/15) in the placebo group, with infusion related reactions and petechiae being the most common. Conclusion: CM313 showed a favourable safety profile and encouraging efficacy in adults with persistent or chronic primary immune thrombocytopenia, characterised by rapid increase in platelet count, sustained platelet responses, and manageable adverse events. Trial registration: ClinicalTrials.gov NCT06199089 .